Kolekalciferol Teva (Colecalciferol)

Colecalciferol (vitamin D3) is first hydroxylated in the liver to 25‑hydroxyvitamin D, then in the kidneys to the active hormone 1,25‑dihydroxyvitamin D. This active form binds to nuclear vitamin D receptors, increasing transcription of calcium‑binding proteins in the intestine, which enhances calcium and phosphate absorption and promotes bone mineralization.

The appropriate dose of Kolekalciferol Teva is determined by a qualified healthcare professional based on the individual’s serum vitamin D level, age, clinical condition, and any concomitant medications. Patients should follow the prescriber’s instructions and not self‑adjust the dosage.

Safety data for colecalciferol in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Healthcare providers should evaluate the risk‑benefit ratio before prescribing it to pregnant or nursing women, and use the lowest effective dose if deemed necessary.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including any cold‑chain requirements), and assist with import documentation.

Kolekalciferol Teva contains colecalciferol (vitamin D3), which is the natural form of vitamin D produced in skin after sunlight exposure and is generally considered more potent and longer‑acting than vitamin D2 (ergocalciferol). Its efficacy in raising serum 25‑hydroxyvitamin D levels is comparable to other high‑quality D3 supplements, while formulation and regulatory status may differ.

Store Kolekalciferol Teva at temperatures below 25 °C in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments to maintain stability and potency.

Kolekalciferol Teva is taken orally, usually with or without food, as directed by a healthcare professional. The tablet should be swallowed whole with a glass of water. Patients should not crush or chew the tablet unless specifically instructed.

The most serious risks include severe hypercalcemia, which can lead to cardiac arrhythmias, renal failure, or vascular calcification, and hypervitaminosis D resulting from excessive dosing. Patients should be monitored for symptoms such as persistent nausea, vomiting, weakness, or abnormal laboratory values and seek medical attention if they occur.

Individuals with known hypersensitivity to colecalciferol or any excipients in the formulation should avoid the product. Patients with conditions predisposing them to hypercalcemia, such as sarcoidosis, primary hyperparathyroidism, or severe renal impairment, should use it only under close medical supervision.